NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.

Zelenetz, Andrew D; Ahmed, Islah; Braud, Edward Louis; Cross, James D; Davenport-Ennis, Nancy; Dickinson, Barry D; Goldberg, Steven E; Gottlieb, Scott; Johnson, Philip E; Lyman, Gary H; Markus, Richard; Matulonis, Ursula A; Reinke, Denise; Li, Edward C; DeMartino, Jessica; Larsen, Jonathan K; Hoffman, James M

Zelenetz, Andrew D; Ahmed, Islah; Braud, Edward Louis; Cross, James D; Davenport-Ennis, Nancy; Dickinson, Barry D; Goldberg, Steven E; Gottlieb, Scott; Johnson, Philip E; Lyman, Gary H; Markus, Richard; Matulonis, Ursula A; Reinke, Denise; Li, Edward C; DeMartino, Jessica; Larsen, Jonathan K; Hoffman, James M.

J Natl Compr Canc Netw ; 9 Suppl 4: S1-22, 2011 Sep.

Article in En | MEDLINE | ID: mdl-21976013

Subject(s)

Antineoplastic Agents/therapeutic use; Biosimilar Pharmaceuticals/therapeutic use; Drug Approval/legislation & jurisprudence; Antineoplastic Agents/adverse effects; Antineoplastic Agents/economics; Biosimilar Pharmaceuticals/adverse effects; Biosimilar Pharmaceuticals/economics; Drug Approval/organization & administration; Drugs, Generic/economics; Drugs, Generic/therapeutic use; Europe; Humans; Neoplasms/drug therapy; United States; World Health Organization

Search on Google

Add to My VHL

XML

PubMed Links

Database: MEDLINE Main subject: Drug Approval / Biosimilar Pharmaceuticals / Antineoplastic Agents Type of study: Guideline / Prognostic_studies Limits: Humans Country/Region as subject: America do norte / Europa Language: En Journal: J Natl Compr Canc Netw Journal subject: NEOPLASIAS Year: 2011 Type: Article

Search on Google

Add to My VHL

XML

PubMed Links